High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.
about
CLImAT: accurate detection of copy number alteration and loss of heterozygosity in impure and aneuploid tumor samples using whole-genome sequencing data.Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumorsnbCNV: a multi-constrained optimization model for discovering copy number variants in single-cell sequencing data11q deletion in neuroblastoma: a review of biological and clinical implications.Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping dataThe role of complex genomic alterations in neuroblastoma risk estimation.Ultra-High Density SNParray in Neuroblastoma Molecular DiagnosticsControl-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing dataAutocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltrationTumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 geneSequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma.Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma.Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability.The role of intracellular calcium for the development and treatment of neuroblastoma.Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications.COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.High genomic instability predicts survival in metastatic high-risk neuroblastoma.The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectGenome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumorsThe microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytesClinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcomaNeuroblastoma and MYCNPrecise inference of copy number alterations in tumor samples from SNP arrays.Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.Genetic stratification of neuroblastoma for treatment tailoring.The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.New insights into the genetics of neuroblastoma.
P2860
Q30824888-ADB1340C-FDFA-4C5F-8D8D-8861ADA3A218Q31030415-79B76B77-7CA7-4629-A863-EE8E732CAF7AQ31131418-375CD46D-1FA0-4474-B13A-708CD7724EF8Q32174267-4E1312C3-C6DA-4723-9723-C1B42454B157Q33659849-B95DC399-5366-46A0-87BB-CE918779C8D2Q33698545-5783947E-DB1C-4745-B6E2-AE37588F6781Q33918821-01BDBD7F-D964-455D-81A7-44B0B0E8DDACQ34032495-F6D3A78D-BAD2-412A-A7AB-0C19135D7AF1Q34095905-9D95F87A-18E5-413C-931A-CAE818D4BD2DQ34140169-26D5C283-0369-402E-852B-59F268446C5FQ34346730-91B5725B-03DE-4AC4-B5F8-9D31C57331DCQ34531771-6C0AA39F-7C00-463C-8315-C5D9910D5A8EQ34558670-EA146B47-5945-416B-8476-2AB5FA891950Q34711056-840C182A-914A-4866-BB1E-42B8B215A549Q34953372-A949C44A-6202-40B4-B1F2-B5FEE6F6A8B1Q35006926-6A293632-9438-4EA4-8E3E-04C06FE5C102Q35082400-696A24C2-1BF6-4621-990D-B7D856D7380DQ35653969-B896D8FF-1AC7-43FA-B63B-9ED9892DEE6EQ35677257-1172675B-97F1-46A3-A737-E6874B0995ACQ35754243-2FA40E77-D5DC-465E-B430-1AC1B83FC36CQ35803084-2670492C-58BA-4B82-88C8-E3A386A58306Q35818437-E35E75C6-717D-41A9-8B50-897700745CCEQ35818443-DE8E41A9-8A95-457C-B5C1-525BA9ECBE09Q35818767-AF3A7EE9-FBAB-4375-B70A-3E8DE203C20EQ36101495-13243FB8-4108-4074-9D5C-BCE59022759BQ36282735-A9C56C97-B14F-4CC6-9039-DDE0E4DE9B66Q36383883-7AD4CFF0-8014-4A67-BC43-E5FE9A2630C6Q36387812-58FDE010-523E-4A7C-97B5-64F6EF17E060Q36838937-8CC0CC31-6B4D-4A55-90C9-365C7C3EA562Q36866183-CD4E40D8-27B7-4ED6-83FD-690EE09A1B88Q36910335-7EB18EB8-95ED-471C-81DF-CB9E9282290BQ37105296-82CA48EA-D1C8-4388-99BC-0768939DBEE2Q37154010-E3F0F3BD-4A84-4B65-A540-955CDC68F630Q37200438-F9E70ABA-08C4-45C3-95A1-EE1B8A376EF7Q37201479-9CAE7C3E-D0B1-4F0A-A2C4-661A498423B5Q37327531-6A295014-A3EB-4114-A65A-2FCCFF7D41E0Q37628972-3FBBEA64-9E5D-4D51-93AE-448D27F0A074Q37932545-9CE1781D-A2F2-4CD4-B192-D3A4C627D447Q38070334-B3B713DF-0A9F-4A30-A42D-E6A57C46DCBDQ38074875-F215153C-D84C-4A08-A08A-2A09DB6E4B08
P2860
High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
High-risk neuroblastoma tumors ...... ty phenotype with later onset.
@ast
High-risk neuroblastoma tumors ...... ty phenotype with later onset.
@en
type
label
High-risk neuroblastoma tumors ...... ty phenotype with later onset.
@ast
High-risk neuroblastoma tumors ...... ty phenotype with later onset.
@en
prefLabel
High-risk neuroblastoma tumors ...... ty phenotype with later onset.
@ast
High-risk neuroblastoma tumors ...... ty phenotype with later onset.
@en
P2093
P2860
P50
P356
P1476
High-risk neuroblastoma tumors ...... ty phenotype with later onset.
@en
P2093
Catarina Träger
Hanna Kryh
Jonas Abrahamsson
Maria Nethander
Per Kogner
Rose-Marie Sjöberg
P2860
P304
P356
10.1073/PNAS.0910684107
P407
P577
2010-02-09T00:00:00Z